Tue, July 20, 2010
[ Tue, Jul 20th 2010 ] - Market Wire
00 AM EDT
Mon, July 19, 2010
Sun, July 18, 2010
Sat, July 17, 2010
Fri, July 16, 2010
Thu, July 15, 2010
Wed, July 14, 2010
Tue, July 13, 2010
Mon, July 12, 2010
Fri, July 9, 2010
Thu, July 8, 2010
Wed, July 7, 2010
Tue, July 6, 2010
Mon, July 5, 2010
Fri, July 2, 2010
[ Fri, Jul 02nd 2010 ] - Market Wire
Celgene????Abraxis BioScience??
Thu, July 1, 2010
Wed, June 30, 2010
Tue, June 29, 2010

Cerus to Release Second Quarter Results on July 29, 2010


//health-fitness.news-articles.net/content/2010/ .. ease-second-quarter-results-on-july-29-2010.html
Published in Health and Fitness on Monday, July 12th 2010 at 5:45 GMT by Market Wire   Print publication without navigation


CONCORD, Calif.--([ BUSINESS WIRE ])--Cerus Corporation (NASDAQ:CERS) announced today that its second quarter 2010 financial results will be released on Thursday, July 29, 2010, after the close of the stock market. The company will host a conference call and webcast at 4:15 p.m. ET that afternoon, during which management will discuss the Company's financial results and provide a general business overview and outlook.

To access the live webcast, please visit the Investor Relations page of the Cerus web site at [ http://investor.cerus.com ]. Alternatively, you may access the live conference call by dialing 877-407-0782 (U.S.) or 201-689-8567 (international).

A replay will be available on the companya™s web site, or by dialing 877-660-6853 (U.S.) or 201-612-7415 (international) and entering account number 286 and conference ID number 353769. The replay will be available approximately two hours after the call through August 13, 2010.

ABOUT CERUS

Cerus Corporation is a biomedical products company focused on commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT system is designed to reduce the risk of transfusion-transmitted diseases by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood. The nucleic acid targeting mechanism of action enables INTERCEPT treatment to inactivate both established transfusion threats, such as hepatitis B and C, HIV, West Nile virus and bacteria, as well as emerging pathogens such as influenza, malaria and dengue. Cerus currently markets and sells the INTERCEPT Blood System for both platelets and plasma in Europe, Russia, the Middle East and selected countries in other regions around the world. The INTERCEPT red blood cell system is in clinical development. See [ http://www.cerus.com ] for more information.

INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.


Publication Contributing Sources